Lantheus Holdings Inc. (LNTH)
LNTH trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/0001193125-26-073498-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LNTH on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001521036 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.5B |
| Net income | $233.6M |
| Operating income | $310.8M |
| Net margin | 15.2% |
| Operating margin | 20.2% |
| Revenue growth | +0.5% |
| Cash | $359.1M |
| Total assets | $2.2B |
| P/E (computed) | 28.5× |
| P/S (computed) | 4.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $683.6M cash; operating cash flow $102.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 65,401,413 (2026-11-02); 66,311,779 a year earlier; 68,489,153 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $389.9M | $22.4M | $102.0M | $683.6M | $571.7M | $1.6B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $388.2M | $75.0M | $92.2M | $593.3M | $571.1M | $1.6B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $377.3M | $118.4M | $125.1M | $498.6M | $570.4M | $1.5B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $406.8M | $54.1M | $90.2M | $359.1M | $569.4M | $1.5B | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $384.0M | $27.8M | $105.3M | $382.0M | $568.8M | $1.5B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $378.0M | $78.8M | $87.1M | $695.6M | $567.6M | $1.5B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $372.8M | $72.9M | $107.6M | $938.5M | $566.8M | $1.5B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $391.1M | -$11.8M | $157.7M | $912.8M | $566.3M | $1.5B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2020-05-14 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-10-02 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.0% |
| 1 month | +1.6% |
| 3 months | +0.6% |
| Year to date | +52.7% |
| 1 year | +91.2% |
| From 52-week high | -8.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ORKA | Oruka Therapeutics Inc. | $99.24 | -5.80% | $6.7B |
| NEOG | Neogen Corporation | $10.88 | -3.12% | $2.4B |
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| IDXX | IDEXX Laboratories Inc. | $700.65 | -0.51% | $55.2B |
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier